Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer – final results from the randomized phase II trial of the AIO

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Thomas Ettrich

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T.J. Ettrich1, A.W. Berger1, T. Decker2, R.D. Hofheinz3, V. Heinemann4, T. Hoffmann5, H.F. Hebart6, T. Herrmann7, C. Hannig8, P. Büchner-Steudel9, H. Bartholomäus1, M. Güthle1, L. Perkhofer1, T. Seufferlein1

Author affiliations

  • 1 Department Of Internal Medicine I  , Ulm University, 89081 - Ulm/DE
  • 2 Private Practice, Onkologie Ravensburg, 88212 - Ravensburg/DE
  • 3 Interdisciplinary Tumor Center, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 4  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 5 Internal Medicine Ii, Klinikum Weimar, Weimar/DE
  • 6 Department Of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, 73557 - Mutlangen/DE
  • 7 Medizinische Klinik, Westküstenklinikum Heide, 25746 - Heide/DE
  • 8 Private Practice, Schwerpunktpraxis Haematologie / Onkologie, 46236 - Bottrop/DE
  • 9 Internal Medicine I, Martin-Luther-University Halle-Wittenberg, 06120 - Halle/DE
More

Resources

Background

Anti-VEGF agents in combination with chemotherapy improve PFS of patients with mCRC in the 1st- and 2nd-line-setting. During anti-VEGF treatment tumour angiogenesis is driven by other factors but VEGF. Nintedanib is a triple angiokinase inhibitor of human VEGFR-1-3, FGFR-1/-3 and PDGFR-α/-β thereby additionally targets angiogenic escape mechanisms upon resistance to anti-VEGF treatment. The TRICC-C trial evaluates the combination of mFOLFOX6 plus Nintedanib. Final results of the randomized phase II trial are presented.

Methods

Patients with mCRC having received one line of non-oxaliplatin containing palliative chemotherapy, with an ECOG-PS of 0 or 1 were randomized 1:1 in a double-blind design to receive: mFOLFOX6 plus Nintedanib (2 x 200 mg p.o./d, d1-d14) or placebo, respectively, repeated every 14 days. Primary endpoint was PFS. Secondary endpoints were ORR, OS and safety. Patients who received at least one dose of trial medication were included in the efficacy and safety analyses.

Results

From 12/2012 to 5/2016 53 patients (scheduled n = 180) were randomized. The trial was terminated prematurely due to slow accrual. Compared to mFOLFOX6 plus placebo (F+P), the combination of mFOLFOX6 plus Nintedanib (F+N) improved mPFS (F+P: 4.6 vs F+N: 8.1 mo.; HR 0.65; 95% CI 0.32-1.30; p = 0.2156), mOS (F+P: 9.9 vs. F+N: 17.1 mo.; HR 1.03, 95% CI 0.48-2.23; p = 0.9387) and DCR (F+P: 50 vs. F+N: 66,7%; p = 0.2709). ORR was comparable in both arms (F+N: 3.8 vs. F+P: 3.7%). Toxicity was low to moderate without major differences between both arms except G 3/4 neutropenia (F+N: 19%, F+P: 12%) and GI disorders (F+N: 23%, F+P: 15%).

Conclusions

Final results suggest a PFS, OS and DCR benefit for mFOLFOX6 + Nintedanib vs. mFOLFOX6 + placebo in the 2nd-line therapy of mCRC. Due to the premature termination of the trial there was no statistical significance demonstrable. Showing no clinically significant PFS-benefit in the 1st-line situation (mFOLFOX6 plus Nintedanib/Bevacizumab, Ann Oncol. 2015) or the last line as single agent, respectively (ESMO 2016) the TRICC-C results suggests that Nintedanib could be an interesting therapeutic option for the 2nd-line situation in combination with mFOLFOX6.

Clinical trial identification

NCT01362361.

Legal entity responsible for the study

Martin-Luther-Universität Halle-Wittenberg, Germany.

Funding

Boeringer Ingelheim.

Editorial Acknowledgement

Disclosure

T.J. Ettrich: Research grants: Baxalta/Shire; Consulting fees or other remuneration: Merck-Serono, Sanofi, Sirtex, Medical, Novartis, Bayer, Bristol-Myers Squibb, Pfizer. A.W. Berger: Consulting fees: Sanofi. R.D. Hofheinz: Consulting or advisory role: Boehringer Ingelheim. T. Seufferlein: Research Funding: Celgene, Sanofi Consulting or Advisory role: Celgene, Lilly Pharma, Boehringer Ingelheim, Merck Serono, Amgen. All other authors have declared no conflicts of interest.

Resources from the same session

Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?

Presenter: Shinsuke Nagasawa

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma

Presenter: ASHA KARIPPOT

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings